Join Us at ISPOR Europe
Connect with Evidera and CorEvitas experts specializing in health economics and outcomes research (HEOR), health economics and market access (HEMA), patient-centered research (PCR), and real-world data (RWD) and evidence (RWE). Our multi-disciplinary team was purpose-built to provide integrated solutions across the product development and commercialization lifecycle. Our deep expertise and proprietary real-world data offerings are designed to simplify your complex research needs, providing seamless support from initial development to market access.
Visit us at Booth # 901 or schedule a meeting on-site to discuss our customized offerings.
Are you ready for the EU HTA Regulation changes?
Book a free consultation at ISPOR EU with our health economic and value access experts to discuss the complex nuances of the evolving EU market access landscape. Let our experts help you navigate the implications of the new regulation to uncover potential hurdles in your HTA strategy.
Request a meeting
Private Workshops at ISPOR EU – RSVP to attend
Our Solutions
Which patient engagement strategies will optimize your clinical study?
Can our real-world data and evidence solutions fast-track approval and secure market access for your asset?
Are you ready for the new EU HTA Regulation changes?
HEOR Theatre Presentation
Tuesday, 19 November • 3:45pm – 4:15pm
Poster and Exhibit Hall, 021, Level P0, Theater 2
Better and Faster: Automating Model Building and Statistical Analyses
Presenters: Jack Ishak, Apoorva Ambavana
Moderator: Agnes Benedict
ISPOR Forum
Tuesday, 19 November • 11:45am – 12:45pm
Using Health Preference Methods for Value Clarification in Patient Decision Support: Current Use and Future Developments
Speaker: Caitlin Thomas
Symposia & Workshop Sessions
Session 2
Monday, 18 November • 5:00pm – 6:00pm
How Do We Unleash the Ambition of the EU HTA Regulation through Practical Methodological Solutions?
Moderator: Martin Parkinson
Panelists: Anna Chaimani, Niklas Hedberg, James Ryan
Session 3
Tuesday, 19 November • 1:45pm – 2:45pm
How Can We Move from Generating Robust Patient Preference Information to Producing Decision-Ready Outputs?
Discussion Leader: Sebastian Heidenreich
Discussants: Paul Schneider, Divya Mohan
Session 4
Tuesday, 19 November • 5:00pm – 6:00pm
Interplay Between Budget Impact Analysis (BIA) and Cost-Effectiveness Analysis (CEA); Theory vs Practice
Moderator: Cornelis Boersma
Panelists: Jaime Caro, Josephine Mauskopf, Thea van Asselt
Session 5
Wednesday, 20 November • 10:00am – 11:00am
Taking the “Greener” Pill – a Case Study for Incorporating Carbon Footprint in Health Technology Assessment
Discussion Leader: Ruth Chapman
Discussants: Michael Cohen, Grace Hampson, Kinga Marczell
Poster Presentations
Session 1
Monday, 18 November
Authoring of Peer-Reviewed Articles on the Experiences of Patients With Rare Diseases by Patients and Their Caregivers: A Rapid Review
Phil Leventhal, Danielle Drachmann, Rienne Schinner, Soren Skovlund
Validation of a Questionnaire to Assess Emotional Impact of Treatment for Type 2 Diabetes (EIDTQ)
Louis Matza, Katelyn Cutts, Karen Malley, Karin Coyne
Patient Preferences of Health State Utilities Associated With Glycemic Variability in People Living With Type 1 and Type 2 Diabetes
Louis Matza, Katie Stewart
A Systematic Literature Review of Economic Burden and Medication Adherence With Subcutaneous Versus Intravenous Oncology Therapies
Carolina Casañas Comabella, Phil Sarocco
Understanding physicians decision making processes when treating mild-to-moderate chronic kidney disease: A qualitative study
Keila Meginnis
Does Baseline Disease Severity Impact the Meaningful Score Difference of Clinical Outcome Assessments? Results From Studies in Two Itching-Related Skin Conditions
Danielle Rodriguez, Carla Dias-Barbosa, Karen Bailey, Dina Filipenko
The Burden of Long COVID on Quality of Life and Daily Functioning
Naomi Stapleton, Heather Burnett, Jennifer Knight
Estimated Cost of Automated Red Cell Exchange Transfusion (ARCET) for Treatment of Sickle Cell Disease (SCD) in the English NHS: Data from a Longitudinal Real-World Cohort
Caoimhe Rice, Sara Carvalho, Jennifer Davidson
Polihexanide and betaine (PSGX) containing solution versus saline for the treatment of leg uclers: A comparative cost analysis study using real-world data from England
Caoimhe Rice, Jennifer Davidson
Session 2
Monday, 18 November
Artificial Intelligence Tools for PICO Prediction: A New Reality or a Future Dream?
Himani Jaiswal, Paulina Rolska-Wójcik, Caroline Delaitre-Bonnin
Patient Preferences and Health State Utilities Associated With Frequency of Basal Insulin Administration for Type 1 and Type 2 Diabetes
Katie Stewart, Louis Matza
Incidence of Solar Retinopathy and Photokeratitis in Private Clinic Post 2017 and 2024 Solar Eclipses Across the USA
Nick Boucher
Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses
Paulina Kazmierska, George Bungey
Real-world Healthcare Resource Utilization and Costs in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in China
Lu Ban
Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-Small Cell Lung Cancer (NSCLC)
Ashwin Rai, Victoria Ikoro, Ariel Berger
How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US)
Ariel Berger
Session 3
Tuesday, 19 November
A Framework for Re-Thinking Evidence Generation Requirements in the United States: It’s Time to Meet Expectations of the Inflation Reduction Act
Anna D’Ausilio, Rhythm Arora, Brian Connelly, Ariel Berger, Haripriya Jain
Representativeness and Coverage of Death Data in the DeSC Healthcare Database in Japan
Ayumi Hamaguchi, Amanda Pulfer, Dimitra Lambrelli
Understanding the Patient Experience in Early Breast Cancer (eBC): A Review of Patient-Reported Outcomes Measures (PROMs) Used in Real-World Evidence (RWE)
Ashley Duenas, Claudine Clucas, Klaudia Kornalska, Paul Swinburn
Session 4
Tuesday, 19 November
Leveraging the DeSC Healthcare Database for Alzheimer’s Disease (AD) Research in an Aging Population in a Real-World Setting in Japan
Ayumi Hamaguchi, Amanda Pulfer, Dimitra Lambrelli
Development of a US-Based, Real-World, Ophthalmology Registry Based on Automated EHR Data Extraction to Support Opportunities for Clinical and Health Economics and Outcomes Research in Eyecare
Nick Boucher, Ariel Berger
Characteristics of Ovarian Cancer Patients: A Real-World Perspective for 1st Line Maintenance Treatment Choice After 1st Line Platinum Based Induction Therapy Across EU4 & UK
Karina Palhares
Deriving an Analytical Solution to Inversion of Royston/Parmar Restricted Cubic Spline Parametric Survival Models for Discrete Event Simulation
George Bungey, Jorgen Moller
How to Manage the Multiple PICOs and Challenging Timelines in Systematic Reviews for JCA Submissions
Sohan Deshpande
Feasibility of GPT-4-Based Content Extraction to Identify Eligible Titles and Abstracts in a Systematic Literature Review (SLR)
Lalith Mittal
Automated Extraction of Cost-Effectiveness Models Data from Health Technology Assessment Submissions Using Large-Language Models (LLMS): Does the Prompting Approach Matter?
Gabor Szabo, Amy Pinsent, Mahmoud Slim, Shannon Sullivan, Agnes Benedict, Simone Rivolo
Long COVID: A Costly Condition Imposing Substantial Burden on Society
Jennifer Knight, Heather Burnett, Naomi Stapleton
Gap Analysis of Patient-Reported Outcome Measures for Systemic Lupus Erythematosus
Milena Anatchkova, Tsion Fikre
Session 5
Wednesday, 20 November
Assessment of Health State Utilities Associated With Being a Caregiver for a Person With Alzheimer’s Disease With Mild Cognitive Impairment or Dementia
Louis Matza, Timothy Howell
Unlocking the Potential of Interoperable Linked Low-Latency National Health Data in England to Protect Vulnerable Patients While Safeguarding their Privacy: A Brave New World
Nahila Justo, Yi Lu, Kathryn Evans, Valerie Olson, David Turner
Automated Data Extraction in Systematic Literature Reviews (SLRs): Assessing the Accuracy and Reliability of a Large Language Model (LLM)
Carolina Casañas Comabella
Improper Age-Adjustment of Health State Utilities in Cost-Effectiveness Models: Assessing the Impact and Key Drivers
Walter Morris, George Bungey
Searching Clinical Trial Registries in Systematic Literature Reviews (SLR): Which and Why?
Lalith Mittal
Estimated Incremental Direct All-Cause Healthcare Costs Associated with Multimorbidity Amongst Patients with Sickle Cell Disease (SCD) in England
Caoimhe Rice, Sara Carvalho, Jennifer Davidson
Understanding the experiences of people living with chronic pruritus of unknown origin: Development of a disease conceptual model
Carla Dias Barbosa, Karen Bailey
Development of a Conceptual Disease Model of the Patient Experience of Systemic Lupus Erythematosus
Milena Anatchkova, Tsion Fikre